REDUCED MORTALITY RATES WITH ANTI-TUMOR NECROSIS FACTOR ALPHA DIRECTED THERAPY WHEN COMPARED TO PROLONGED CORTICOSTEROID THERAPY FOR INFLAMMATORY BOWEL DISEASE

被引：2
|
作者：
Lewis, James D.
Scott, Frank I.
Brensinger, Colleen M.
Roy, Jason A.
Osterman, Mark T.
Mamtani, Ronac
Chen, Lang
Yun, Huifeng
Xie, Fenglong
Curtis, Jeffrey R.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)30570-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
247
引用
收藏
页码：S64 / S65
页数：2
相关论文
共 50 条
  • [41] How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
    Mark G Ward
    Peter M Irving
    Miles P Sparrow
    World Journal of Gastroenterology, 2015, (40) : 11331 - 11342
  • [42] Syphilis in the Setting of Anti-tumor Necrosis Factor Alpha Therapy
    Iglesias-Plaza, Ana
    Iglesias-Sancho, Maribel
    Quintana-Codina, Monica
    Garcia-Miguel, Javier
    Salleras-Redonnet, Montse
    REUMATOLOGIA CLINICA, 2019, 15 (06): : E108 - E110
  • [43] Infection and anti-tumor necrosis factor-alpha therapy
    Zandman-Goddard, G
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2003, 5 (11): : 814 - 816
  • [44] Gain weight with anti-tumor necrosis factor alpha therapy
    Vincent, C.
    Betegnie, A.
    Grange, L.
    Courieres, S. Barbou Des
    Fiacre, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 86 - 86
  • [45] Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
    Lew, Daniel
    Yoon, Soon Man
    Yan, Xiaofei
    Robbins, Lori
    Haritunians, Talin
    Liu, Zhenqiu
    Li, Dalin
    McGovern, Dermot P. B.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (40) : 7265 - 7273
  • [46] REAL-WORLD TREATMENT PATTERNS WITH ANTI-TUMOR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE IN ISRAEL
    Weil, C.
    Chodick, G.
    Yarden, A.
    Khalid, J. M.
    Shalev, V
    VALUE IN HEALTH, 2016, 19 (07) : A509 - A510
  • [47] Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2019, 157 (04) : 922 - 924
  • [48] Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
    Daniel Lew
    Soon Man Yoon
    Xiaofei Yan
    Lori Robbins
    Talin Haritunians
    Zhenqiu Liu
    Dalin Li
    Dermot PB McGovern
    World Journal of Gastroenterology, 2017, (40) : 7265 - 7273
  • [49] Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
    Kim, Jihye
    Im, Jong Pil
    Yim, Jae-Joon
    Lee, Chang Kyun
    Park, Dong Il
    Eun, Chang Soo
    Jung, Sung-Ae
    Shin, Jeong Eun
    Lee, Kang-Moon
    Cheon, Jae Hee
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (01): : 29 - +
  • [50] Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies
    Fernando Magro
    Francisco Portela
    BioDrugs, 2010, 24 : 3 - 14
12345